What defines the opportunity?
Disease context, treatment paradigm, biomarker biology, testing pathway, mechanism, and cohort assumptions.
INTELLIGENCE
A connected evidence system built around the decision—not the dataset.
OncoLattice links oncology entities, relationships, time, derived signals, corrections, and review history so every analysis does not start from zero.
Four evidence dimensions strengthen one development view.
The weighting changes with the decision. The evidence architecture does not.
What else is moving?
Active studies, upcoming readouts, exact-site footprints, competing cohorts, and sponsor activity.
Where can the protocol work?
Institution capability, PI relevance, phase and disease experience, competitive burden, and execution context.
Does patient reality support the signal?
Population distribution, treatment history, geography, access, biomarker context, and clinical evidence where permitted.
THE FOUNDATION BEHIND THE MODEL
Structured, selective, time-aware intelligence.
The database is infrastructure beneath the experience. It makes evidence reusable, traceable, and comparable without becoming the product story itself.
Connected Entities
Assets and protocols, biomarkers and mechanisms, trials, exact sites, investigators, sponsors, and geographies.
Relationship Graph
Sponsor–site history, PI–site affiliations, trial–publication links, collaborator networks, and disease–mechanism relationships.
Temporal History
Source snapshots, trial-status changes, site activity, affiliation changes, and recent-versus-prior signals.
Derived Intelligence
Protocol-fit features, rankings, execution signals, competitive burden, confidence, supporting evidence, conflicts, and unknowns.
Review status, corrections, unresolved conflicts, and validation history remain linked to the evidence.
The intelligence layer resolves into five things a decision owner can use.
01Rankings02Recommendations03Risks04Confidence05Next actions
START WITH ONE DECISION
A focused pilot begins with a fixed question.
The first engagement is designed to produce an independent signal that can be compared with the sponsor's or CRO's current view.
Outputs are for strategic planning and do not guarantee patient availability, enrollment, site performance, regulatory outcomes, or clinical success.